Chaim Indig Sells 3,089 Shares of Phreesia, Inc. (NYSE:PHR) Stock

Phreesia, Inc. (NYSE:PHR) CEO Chaim Indig sold 3,089 shares of the stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $21.03, for a total transaction of $64,961.67. Following the completion of the sale, the chief executive officer now owns 1,220,647 shares in the company, valued at approximately $25,670,206.41. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Chaim Indig also recently made the following trade(s):

• On Tuesday, September 10th, Chaim Indig sold 5,295 shares of Phreesia stock. The stock was sold at an average price of $23.25, for a total transaction of $123,108.75.
• On Monday, July 29th, Chaim Indig sold 7 shares of Phreesia stock. The stock was sold at an average price of $24.75, for a total transaction of $173.25.

Phreesia Stock Performance

Shares of PHR stock traded down $0.45 during midday trading on Thursday, hitting $20.40. 434,344 shares of the company were exchanged, compared to its average volume of 450,865. The firm has a market capitalization of $1.17 billion, a P/E ratio of -9.45 and a beta of 0.93. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.77 and a current ratio of 1.77. The firm’s 50 day moving average price is $23.40 and its two-hundred day moving average price is $22.45. Phreesia, Inc. has a 52 week low of $12.05 and a 52 week high of $29.16.

Phreesia (NYSE:PHR) last issued its quarterly earnings data on Wednesday, September 4th. The company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.06. Phreesia had a negative net margin of 25.73% and a negative return on equity of 39.34%. The business had revenue of $102.12 million during the quarter, compared to analysts’ expectations of $101.76 million. As a group, equities research analysts anticipate that Phreesia, Inc. will post -1.23 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on PHR. Robert W. Baird raised their price objective on shares of Phreesia from $31.00 to $34.00 and gave the stock an “outperform” rating in a report on Friday, September 6th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $23.00 target price on shares of Phreesia in a research report on Friday, September 27th. Truist Financial raised their target price on shares of Phreesia from $29.00 to $31.00 and gave the company a “buy” rating in a research report on Friday, September 6th. JMP Securities reaffirmed a “market outperform” rating and issued a $30.00 target price on shares of Phreesia in a research report on Thursday, September 5th. Finally, KeyCorp decreased their target price on shares of Phreesia from $27.00 to $25.00 and set an “overweight” rating for the company in a research report on Thursday, July 11th. One equities research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $29.42.

Hedge Funds Weigh In On Phreesia

Several hedge funds and other institutional investors have recently made changes to their positions in PHR. nVerses Capital LLC raised its position in shares of Phreesia by 76.5% in the 2nd quarter. nVerses Capital LLC now owns 3,000 shares of the company’s stock valued at $64,000 after buying an additional 1,300 shares in the last quarter. EntryPoint Capital LLC acquired a new position in shares of Phreesia in the 1st quarter valued at approximately $169,000. Quadrature Capital Ltd acquired a new position in shares of Phreesia in the 1st quarter valued at approximately $202,000. Lombard Odier Asset Management USA Corp acquired a new position in Phreesia during the 2nd quarter worth approximately $202,000. Finally, Point72 DIFC Ltd acquired a new position in Phreesia during the 2nd quarter worth approximately $209,000. 92.10% of the stock is currently owned by institutional investors and hedge funds.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.